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Abstract
The high recurrence and progression rates in
superficial bladder cancer are partially related to the
deficiencies of the standard conventional diagnostic
modalities. Therefore, innovative noninvasive and
invasive detection devices have been studied during
the last decade. New diagnostic urine markers are
under intensive investigation in order to exclude the
presence of urothelial cancer, but the value of all
these tests is still insufficiently validated in diagno-
sis and follow-up. With the introduction of 5-amino-
levulinic acid fluorescence endoscopy, the efficacy of
the detection device has been significantly im-
proved. Flat lesions such as carcinoma in situ can be
completely detected besides exophytic tumors. This
is of particular importance because the fate of the
patient depends to an important extent on these
tumor entities. Furthermore, first experimental re-
sults using imaging devices like optical coherence
tomography and confocal laser scanning micro-
scopy promise new powerful noninvasive tools for
‘optical sectioning’ of the bladder.
Introduction
Bladder cancer is the sixth most frequent malignant
disease in the world. Superficial stages are found in
approximately 75–85% of the patients upon first diag-
nosis; 50–70% of the patients with superficial tumors
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suffer one or several recurrences after the initial treat-
ment, and in about one third of the patients a progres-
sion is observed [1]. The mechanisms for tumor recur-
rence and/or progression can be summarized as
follows: (1) subsequent new tumor occurrence; (2) im-
plantation of tumor cells at the time of transurethral
resection (TUR); (3) incomplete tumor resection,
and/or (4) overlooking of the concomitant presence of
flat urothelial lesions like dysplasias and carcinomas in
situ [2]. Therefore, the current diagnosis of superficial
bladder cancer requires a thorough review in many
respects.
Conventional Diagnosis of 
Superficial Bladder Cancer
Cytoscopic evaluation of the bladder, routine cytol-
ogy, and random biopsy are the main diagnostic tools
since many decades and can be considered the current
‘gold standard’. Although many aspects of the manage-
ment of superficial bladder cancer are now well estab-
lished, significant challenges remain which influence
the patient outcome. Early detection and treatment of
recurrent disease is required to maximize bladder
preservation and patient survival. Especially in cases of
flat urothelial lesions, conventional endoscopy is not
sufficient to reveal areas of carcinoma in situ or dys-
plasia. However, it is mainly this tumor entity that
determines the patient’s prognosis. If dysplasia or car-
cinoma in situ is found in mucosae of normal appear-
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ance, the risks of suffering a muscle-infiltrating recur-
rence within 4 years are 36 and 83%, respectively [3].
Therefore, early recognition of a carcinoma in situ is
essential to offer the patients the most appropriate
treatment and the highest cure rate.
Cytological investigation of the urine is a noninva-
sive and an important adjunct to the diagnosis of blad-
der cancer. Whereas the sensitivity of cytology is high
for carcinomas in situ and high-grade neoplasms, it is
rather low for low-grade tumors and dysplasias [4].
Nevertheless, the WHO consensus classification from
1999 [5] classified the moderate dysplasia as high-grade
intraurothelial neoplasia like carcinoma in situ.
Moreover, the sensitivity calculations only relate to the
cases in whom visible tumors were present at the same
time. Unfortunately, it is not surprising when Giella et
al. [6] found a sensitivity of only 40% for urine cytol-
ogy in follow-up investigations of bladder cancer
patients.
However, in case of positive cytology and normal
appearing mucosa, random biopsies are recommended
by several authors. In contrast, other investigators
believe that random biopsies are an insufficient
method for detecting flat lesions [7]. In a retrospective
study Kiemeney et al. [8] found no correlation between
patient outcomes whether select mucosal biopsies were
not performed or if done were normal. However, if dys-
plasias or carcinomas in situ were found, the patients
had a statistically significantly higher risk of tumor pro-
gression. Therefore, random biopsies seem to be inad-
equate, since relevant early-stage and precancerous
lesions are often missed [8].
Regardless of the questionable wisdom of obtaining
selected mucosal biopsy specimens, there is no doubt
that the standard repertoire for the detection of flat
lesions requires improvement.
But, however, not only dysplasias and carcinomas in
situ are the potential cause of the high rates of recur-
rence and progression of bladder carcinomas, but also
tumors that have been overlooked or left behind in
TUR.
The risk of overlooking neoplastic lesions of the
bladder using white-light endoscopy is significant.
After TUR of superficial bladder cancers, tumor rem-
nants were found in up to 43% of the cases at repeated
resection 1–2 weeks later [9, 10]. Even in solitary super-
ficial bladder tumors, residual disease was found in
24% of the patients at a second TUR 5 weeks later. The
authors underlined the quality of their first resection by
the fact that the second resection revealed infiltrative
growth in only 2% of the cases. Therefore, most of these
overlooked neoplasms stemmed from positive margins
or heterotopic lesions.
Klän et al. [11] reported a fractionated resection of
T1 transitional cell cancer. In 28% of the patients pos-
itive tumor margins were found, while residual disease
from the tumor base was not observed in any case. A
routine second resection was carried out 8–14 days lat-
er and revealed residual disease in 50% of the patients
despite the surgical report of complete resection. 76%
of the missed lesions were found to be visible tumors at
repeated resection. These authors concluded that the
extent of the lesions can easily be misjudged even by
experienced surgeons.
New Diagnostic Procedures
In view of the above-mentioned deficiencies, during
the last decade efforts have been made to improve the
invasive and noninvasive detection of superficial blad-
der cancers.
Noninvasive Tests
The use of a noninvasive marker test to exclude the
presence of urothelial cancer was extensively investi-
gated in recent years. One of the most studied new
marker tests for bladder cancer is the bladder tumor
antigen (BTA) test. The BTA test is a latex agglutina-
tion assay for the qualitative detection of BTA in the
urine. The antigen is composed of basement membrane
complexes that have been isolated from the urine of
bladder cancer patients. Several groups have investi-
gated the BTA test, but nevertheless its place still
remains unclear, especially in patients with urinary
tract infections [12–14].
Another test used by several investigators is the nu-
clear matrix protein 22 test. Normal subjects have been
shown to have low levels of nuclear matrix protein 22
in their urine as compared with patients with active
bladder cancer. The results showed a high efficacy in
the follow-up of patients with transitional cell carcino-
mas. Nevertheless, the specificity in case of urinary
tract infection or hematuria limits the clinical signifi-
cance [15, 16].
However, many tests (immunostaining of Lewis X,
fibrin degradation products, p53, M344, BLC-4, telom-
erase activity, UBC, HA-HAase) are now under inten-
sive investigation, but the value of all these tests is still
insufficiently validated in diagnosis and follow-up [17].
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Furthermore, most of these tests are labor-intensive,
and costs may limit their use as ancillary techniques in
many institutions in daily routine [18].
Fluorescence Endoscopy
Cytoscopy in combination with the fluorescence
phenomenon of malignant tumors appeared to be one
of the most suitable methods for tumor detection dur-
ing the last decade. Since the 60s urologists have sought
for methods of in vivo labeling of neoplastic lesions, in
order to decrease the risk of overlooking tumors, by
means of an additional color contrast. But in vivo stain-
ing with tetracycline, methylene blue, fluorescein, or
synthetic porphyrin compounds could not be estab-
lished and has been abandoned [19–22].
Since 1992, 5-aminolevulinic acid (5-ALA) is inves-
tigated for fluorescence detection of urothelial cancer.
5-ALA is a precursor of the heme biosynthesis and
induces an accumulation of fluorescent endogenous
porphyrins, mainly protoporphyrin IX (PPIX), in tis-
sues of epithelial origin. PPIX is the decisive dye for
fluorescence detection with an excitation spectrum just
above 400 nm. The fluorescence excitation is provided
by an excitation light source (short-arc xenon lamp)
with a specially designed dielectric short-pass filter
(375–440 nm). Using this light source, the bladder can
be examined under both white light and blue light.
Following intravesical application of 5-ALA, a selective
accumulation of PPIX in urothelial cancer could be
demonstrated, providing an intensive color contrast
between red-fluorescing malignant lesions and the non-
fluorescing normal blue mucosa [23].
The results of 5-ALA fluorescence endoscopy (AFE),
based on a biopsy-related evaluation, showed a signifi-
cant increase in sensitivity for the diagnosis of neo-
plastic urothelial lesions such as dysplasias and carci-
nomas in situ as well as for the diagnosis of papillary
tumors of additional evaluation of porphyrin fluores-
cence. The procedure was characterized by a sensitivi-
ty of 97% and a specificity of 65% [24]. Due to the top-
ical administration of 5-ALA and the fast metabolism,
only minor side effects such as urgency were observed
in about 7% of the cases. The outstanding sensitivity of
the procedure was confirmed by other investigators and
ranges from 87 to 96% [24–29]. Table 1 summarizes the
data published so far.
After these initial encouraging results using 5-ALA
fluorescence endoscopy, the data recently have been
validated in additional cases. In a cohort of 605
patients, 1,012 AFEs were carried out from 1995 until
2000 [30]. More than 50% of these patients presented
with intermediate- and high-risk lesions or suffered
from a recurrent disease. In total, specimens from
2,475 lesions were obtained. The mean biopsy rate was
2.4 per endoscopy. In 552 cases urothelial neoplasms
had been found, 34% of these only due to their positive
fluorescence. Table 2 shows the histopathological
results of the 552 AFEs with malignant findings. The
data demonstrate the superiority of AFE as compared
with white-light endoscopy in case of high-risk urothe-
lial lesions.
In order to investigate whether a 5-ALA-guided
TUR is able to reduce the residual tumor rate, a ran-
domized controlled phase III study was carried out. 165
patients with suspected bladder cancer were random-
ized into two treatment modalities. The follow-up
resection was carried out after 10–14 days with white
light. The percentage of patients rendered free from
tumor at the first resection was defined as the principal
parameter. The analysis of the data showed a signifi-
cant advantage in favor of the AFE-controlled resec-
tion. 67.3% of the patients could be rendered free from
tumors by means of an AFE-controlled resection.
Under conventional conditions using white light, this
proportion was only 46.9%. The number of patients
with residual tumors after a first resection could thus be
reduced by 40% [31].
Authors Number of Number of Enhanced tumor Sensitivity Specificity
patients biopsies detection, % % %
Kriegmair et al. [24] 104 433 38 95.8 63.8
Jichlinski et al. [25] 34 215 76 89 57
Filbeck et al. [26] 55 130 18 87 59
Koenig et al. [27] 123 347 30.3 96 67
Riedl et al. [28] 52 – 25 94.6 43
De Dominicis et al. [29] 49 179 69 87 63
Table 1. Comparison of six clinical 
studies of 5-ALA for the detection of 
bladder carcinomas
sidered tumor precursors that are missed by conven-
tional histology [35]. This aspect is currently investi-
gated intensively in longitudinal and horizontal studies
of biopsy material in order to evaluate systematically
the genetic steps of tumorigenesis and their possible
causal connection with a raised PPIX metabolism.
Furthermore, false-positive responses were fre-
quently obtained from lesions with inflammation or
scarring after prior TUR. This was evaluated by
Filbeck et al. [36] who showed that the granulation tis-
sue limits the procedure within 6 weeks after TUR.
Such lesions are fluorescence positive, but apparently
show a lower fluorescence intensity as compared with
papillary tumors or even carcinomas in situ. Therefore,
methods for fluorescence quantification or the addi-
tional use of autofluorescence have been established
and are now under investigation in order to reduce the
rate of false-positive biopsy specimens [37, 38].
Finally, the number of false-positive results seems to
be acceptable, as in total the mean number of biopsies
is low with 2.4 specimens per patient [30]. In this 
context, however, it is important to emphasize that
white-light endoscopy and fluorescence endoscopy are
complementary and not competing procedures. The
concomitant investigation under blue light enhances
the detection of malignant bladder lesions as compared
with the standard white-light procedure alone.
Recently, D’Hallewin et al. [39] reported first clini-
cal results with a new potent photosensitizer, hypericin.
Hypericin is a hydroxylated phenanthroperylenequin-
one present in a number of plants and is widely dis-
tributed around the world. The hypericin-induced flu-
orescence showed high sensitivity and specificity in the
detection of flat urothelial lesions without any side
effects. The fluorescence excitation was performed
with a xenon-arc lamp designed for the excitation of 5-
ALA-induced PPIX fluorescence. However, larger tri-
als are warranted to prove the diagnostic potential of
this detection device.
Optical Sectioning
The above-mentioned limitations of standard
endoscopy have led investigators to examine other
methods of evaluating the bladder tissue. However
MRI, CT scan, or transabdominal ultrasound are pow-
erful techniques to assess distant metastases or large
extended tumors of the bladder. Unfortunately, they
failed in the detection of small papillary tumors or flat
lesions, and their relatively low resolution prevents
assessment of the degree of tumor invasion in the blad-
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So far, data have proven that AFE: (1) enhances the
sensitivity in the detection of neoplastic urothelial
lesions, and (2) increases the radicality of TUR.
Therefore, a decrease of the recurrence rate is expected
together with an increase in the interval until recurrent
disease takes place. First results have shown so far that
there might be a significant influence on the early
recurrence rates [32, 33]. Meanwhile, a prospective,
randomized multicenter trial is in progress to evaluate
the magnitude of the long-term effects of the fluores-
cence-guided resection as compared with the standard
white-light approach.
Nevertheless, positive fluorescence is not limited to
tumor lesions only. By traditional histology, 34.7% of
the lesions that show specific PPIX fluorescence are
histologically benign [30]. The diagnoses range from
normal and hyperplastic urothelium to cystitis and
squamous metaplasia. The questions that have to be
posed are: (1) Does  this result impair the positive effect
of the technique, and (2)  Is there a chance of false-pos-
itive lesions being partially preneoplastic lesions?
Starting with the latter, it has been shown that false-
positive lesions such as simple hyperplasias have been
known to already exhibit genetic changes identical to
those of papillary tumors of the same patient [34]. The
results obtained by fluorescence in situ hybridization
and loss of heterozygosity analysis indicate that at least
part of the false-positive lesions may have to be con-
Table 2. Histopathological classification of detected tumor le-
sions in 1,012 fluorescence endoscopies [30]
Histology Detected with WLE Detected with AFE WLE and
(overlooked (overlooked AFE
under AFE) under WLE)
pT1G2/3 – 5 37
pT1GIII 3 12 46
pT1GII – 11 26
pT1GI 1 3 9
pTaGIII – 5 11
pTaGII 11 19 80
pTaGI 32 60 178
pTxGIII – 1 6
pTxGII – 2 5
pTxGI 2 1 13
pTxGx – – 1
CIS 4 50 88
Dysplasia II 22 20 52
Total 75 189 552
WLE = White-light endoscopy; CIS = carcinoma in situ.
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Further basic and clinical research is necessary in
order to prove the validity of this ‘optical sectioning’ in
the diagnosis of bladder cancer.
Conclusions
During the last decade, several promising diagnostic
techniques have been studied in order to improve the
current diagnosis of superficial bladder cancer.
However, the 5-ALA fluorescence endoscopy is now an
established procedure. It has proven to be applicable
and cost-effective, especially in the detection of high-
risk flat lesions. A very promising concept could be the
combination of an noninvasive specific marker, a
detection device such as AFE, and ‘optical sectioning’
by optical coherence tomography or confocal laser
scanning microscopy.
der wall. Therefore, recently new imaging devices
based on the ‘optical sectioning’ of tissue have been
investigated.
Optical coherence tomography has been developed
in order to provide in situ high-resolution imaging of
the bladder tissue. This is a technology which performs
realtime, micron scale imaging (4–20 m) near the lev-
el of histopathology. It is analogous to B-mode ultra-
sound, except that it uses infrared light as opposed to
acoustic radiation. First experimental results suggest a
procedure with a potential role envisioned in the man-
agement of transitional cell carcinomas, identifying the
depth of infiltration noninvasively [40, 41].
Confocal laser scanning microscopy is a noninvasive
modality for ‘optical sectioning’ of tissue. It allows
imaging of the urothelium and parts of lamina propria
and lamina muscularis throughout the bladder wall in
vivo. This technique can image nuclear, cellular, and
structural morphological features in thin sections with
lateral and axial resolutions of 0.5–1 and 3–5 m,
respectively [42, 43].
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